( CDXI ) Cardax, Inc. – “Astaxanthin for the Treatment of Osteoarthritis, a Large Unmet Medical Need”

New York, NY / June 10, 2014 / Cardax, Inc. (OTCQB: CDXI) today published a new blog post on The Chairman’s Blog, written by the Company’s Vice President of Research, Dr. Timothy J. King. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends…

In his blog, Dr. King discusses the potential of astaxanthin for the treatment of osteoarthritis, a disease that currently affects approximately 12% of persons 60 years of age or older. He writes, “[astaxanthin] is a safe, orally bioavailable, naturally occurring molecule with strong antioxidant and anti-inflammatory activity.” Read the full blog post from Dr. Timothy J. King on TheChairmansBlog.com (http://www.thechairmansblog.com/cardax/timothy-king/astaxanthin-treatment-osteoarthritis-large-unmet-medical-need/).

About Cardax

Cardax is a development stage life sciences company that devotes substantially all of its efforts to developing nutraceutical and pharmaceutical products that provide the anti-inflammatory benefits of steroids or NSAIDS, but with exceptional safety profiles, as conferred by U.S. Food and Drug Administration (“FDA”) Generally Recognized as Safe (“GRAS”) designation at certain doses. Cardax is preparing proprietary nature-identical products and related derivatives by total synthesis to provide scalable, pure, and economical therapies for diseases where inflammation and oxidative stress are strongly implicated, including, but not limited to, osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease. The initial primary focus of Cardax is its astaxanthin technologies. Astaxanthin is a powerful and safe naturally occurring anti-inflammatory and anti-oxidant without the adverse side effects typical of anti-inflammatory treatments using steroids or NSAIDS, including immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding. http://cardaxpharma.com/

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com


The Wall Street Journal

View original article at: ( CDXI ) Cardax, Inc. – “Astaxanthin for the Treatment of Osteoarthritis, a Large Unmet Medical Need”

Leave a Reply